Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation

Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series

(2016) Attaphol Pawarode et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation

(2016) Karen Ballen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT

(2015) I Ceberio et al.   BONE MARROW TRANSPLANTATION

Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin

(2015) Dionysis Neofytos et al.   CLINICAL INFECTIOUS DISEASES

A registry-based study of non-Aspergillus mould infections in recipients of allogeneic haematopoietic cell transplantation

(2015) M.L. Fox et al.   CLINICAL MICROBIOLOGY AND INFECTION

Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice

(2014) D. Purtill et al.   BLOOD

Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time

(2014) R Parody et al.   BONE MARROW TRANSPLANTATION

Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice

(2014) Claudia Langebrake et al.   CLINICAL TRANSPLANTATION

Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study

(2014) David Nachbaur et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT

(2013) J El-Cheikh et al.   BONE MARROW TRANSPLANTATION

Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression

(2012) Emanuel Severus et al.   BMC Medicine

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation

(2011) David I. Marks et al.   BRITISH JOURNAL OF HAEMATOLOGY

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation

(2010) J. R. Wingard et al.   BLOOD

Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation

(2010) Ted A. Gooley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES

Epidemiology and Outcome of Invasive Fungal Infection in Adult Hematopoietic Stem Cell Transplant Recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance Registry

(2008) D. Neofytos et al.   CLINICAL INFECTIOUS DISEASES

Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation

(2008) Yasushi Hiramatsu et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY